GPX 150

Drug Profile

GPX 150

Alternative Names: CNDO-101; GPX150

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Gem Pharmaceuticals
  • Class Antineoplastics; Doxorubicins
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I Cancer; Solid tumours
  • Preclinical Psoriasis

Most Recent Events

  • 30 Mar 2017 Gem Pharmaceuticals and OncBioMune sign a binding term sheet for a prospective collaboration agreement to develop GPX 150 in Mexico, Central America and Latin America
  • 18 Aug 2016 Gem Pharmaceuticals completes a phase II trial for Soft tissue sarcoma (Metastatic disease) in USA (NCT02267083)
  • 07 Jun 2016 Efficacy and safety data from a phase II trial in Soft tissue sarcoma presented at the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top